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Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62S28volume of cartilage (2359.16  738.72 mm3 for haplogroup T and
2019.59  577.78 mm3 for haplogroup H) (p ¼ 0.009).
Conclusions: This work strength the hypothesis that mitochondrial
genome is a key factor in the progression of the OA disease. The early
identiﬁcation and classiﬁcation of patients with haplogroup T and the
most common haplogroup H would permit to carry out a more
personalized follow-up of the disease.39
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Background: Osteoarthritis (OA), the most common form of arthritis in
the elderly, causes pain, stiffness, a limited range of motion, joint
deformity and disability, and imposes a high economic burden on
society. OA is a multifactorial disease with both genetic and environ-
mental factors involved. A newly-described syndrome called Aneu-
rysm-Osteoarthritis Syndrome (AOS) was recently reported. AOS
presents with early onset OA in multiple joints, together with aneu-
rysms in the major arteries, and is associated with eight rare mutations
in the SMAD3 gene. Because of the similarity with AOS, we hypothe-
sized that SMAD3 is also associated with idiopathic generalized OA
(GOA) and tested our hypothesis in a large OA cohort.
Methods: Study participants were derived from TwinsUK cohort.
Radiographic OA in the hands, knees and hips were assessed using the
Kellgren-Lawrence (K/L) scoring system. Joints with a K&L score2
were deﬁned as affected. GOA patients were deﬁned as those with at
least two joints (hand, knee, or hip) affected. Genotypes on all 41 SNPs
within SMAD3 (genotyped with the Illumina HapMap 610K chip) were
retrieved from the TwinsUK database. A robust logistic regression
model was used to test the association between GOA and SMAD3 with
adjustment for age, BMI, and relatedness.
Results: A total of 204 patients with GOA and 477 individuals without
radiographic OAwere included in the ﬁnal analysis. All 41 SNPs were in
HWE. We found that rs6494629 is strongly associated with GOA, with
an OR of 1.89 (95% CI 1.2-2.8, p¼0.002). Four additional SNPs, all within
100 kb of rs6494629 in the ﬁrst intron, were also associated with GOA
(all p<0.05). In addition, we found rs893473 to be associated with knee
OA (OR¼1.8, P¼0.02, CI¼ 1.09-3.09); rs12913547 (OR¼ 1.5, P¼ 0.025,
CI¼ 1.05-2.35) and rs4601989 (OR¼ 1.4, P¼ 0.041, CI¼ 1.01-2.2) with hip
OA; and rs6494629 (OR¼ 1.44, p¼0.025, CI¼ 1.04-1.9), rs3825977 (OR¼
0.59, p¼ 0.026, CI¼ 0.3-0.9), rs16950687 (OR¼ 0.6, p¼0.035, CI¼ 0.4-
0.9) to be associated with hand OA. The associations with individual
joint OA are weaker compared with GOA.
Conclusion: We demonstrated that variations in the SMAD3 gene are
strongly associated with GOA. Further studies are required to reveal the
potential mechanism for the association.40
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San Francisco, CA, USAPurpose: In the SEKOIA study, strontium ranelate (SrRan) has demon-
strated radiographic structure-modifying activity, by lowering joint
space narrowing progression compared to a placebo group. The aim of
this analysis was to evaluate the effect of SrRan on knee cartilage and
bone in a subset of patients that underwent MRI.
Method: SEKOIA is a large international, randomised, placebo-
controlled phase III, 3-year study. Included patients were men and
women over 50 years of age, with symptomatic primarymedial knee OA
(at least 40 on a 100-mm visual analog scale on most days of the
previous month, a Kellgren and Lawrence [KL] grade 2 or 3, and joint
space width [JSW] of 2.5-5 mm). MRI was performed at inclusion and
then annually in a subset of patients from 36 centers. Images were
centrally read (Synarc Inc, Hamburg, Germany) and the joint tissue
pathology (cartilage morphology, bone edema, subchondral cysts, bone
attrition, osteophytes, meniscal damage, synovial effusion.) was
evaluated semiquantitatively using the WORMS method. SrRan 1g and
SrRan 2g treatment groups were compared to placebo for the change
from baseline to the last value, using a general linear regression model
adjusted with gender, center and baseline values as covariates. Patients
who had a worsening of their score of at least 1 were compared among
groups using a chi2 test.
Results: MRI ITT included 364 patients. At baseline, the mean age was
627years, BMI was 29.94.9 kg/m2, and JSW was 3.50.8 mm. 65%
were KL grade 2 and 67%were female. Therewere no differences among
groups at baseline. Over 3 years, progression in WORMS score occurred
in less than 45% of the patients for cartilage morphology and less than
20% of the patients for other joint features. There were no differences
between treatment groups in mean changes for any parameters. The
number of patients with a deterioration of the cartilage morphology
was signiﬁcantly lower in the SrRan 2g group than in the placebo group
in the lateral compartment (3.4%, 4 patients vs. 15.7%, 19 patients;
p¼0.001). No difference was observed in the medial compartment (25%
vs 27% in the SrRan 2g and placebo groups, respectively).. For bone
features, fewer patients had aworsening of their osteophyte score in the
medial compartment in the SrRan 2g group than in the placebo
group(12.0%, 14 patients vs. 23.0%, 28 patients; p¼0.026), a similar
trend was observed in the lateral compartment (p¼0.085). No statisti-
cally signiﬁcant differences were observed for the SrRan 1g group
compared to placebo (14 patients (11.4%, p¼0.324 for lateral cartilage
morphology, and 23 patients (18.7), p¼0.259) for medial osteophytes).
Despite the small number of patients concerned, numerically fewer
patients had a worsening of bone attrition score in the SrRan 2g group
(2.6% vs. 6.6%) in the medial compartment. Very few meniscal extru-
sions were observed (less than 6 patients per group) over 3 years.
Conclusions: Within the limits of the small number of patients who
have a detectable change, strontium ranelate 2g/day reduces cartilage
degradation and progression of osteophytes, and tends to decrease
bone attrition in patients with knee osteoarthritis.41
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Purpose: There is a putative role of vitamin D in osteoarthritis (OA)
based on animal, epidemiological and human clinical studies. Short
term clinical studies suggest beneﬁcial inﬂuence of vitamin D on local
changes in the bone which probably accounts for diminished pain
experienced in knee OA (KOA). Inadequate sunlight exposure and lower
serum levels of 25(OH)D appears to be associated with an increased risk
for progression of OA knee. Some chronic analgesic users with OA knee
were more likely to be in lower categories of 25(OH) D compared to
women with asymptomatic OA. On the basis of above background this
study was planned to assess the effect of vitamin D on the progression
of disease.
Methods: A six month, double blind, randomized and placebo
controlled trial of vitamin D, in vitamin D insufﬁcient OA knee subjects
(serum 25(OH)D levels <50 nmol/L) was conducted. 150 subjects of
primary OA knee, diagnosed by ACR guidelines, were subjected to
personal interview to determine their vitamin D intake (by 3 day die-
tary recall and food frequency table) and the daily sunlight exposure in
hours. Serum levels of calcium, phosphorus, alkaline phosphatase and
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identiﬁed 64 vitamin D insufﬁcient subjects out of 150 primary OA knee
patients. These were randomized by random allocation table for inter-
vention. In cases a bolus dose of calciferol in 60,000 IU/day for 10 days
followed by 6,000 IU/month for six months was administered and in
controls a placebo in the same schedules and durations was given.
Primary outcome measures were clinical WOMAC scores (pain, stiffness
and physical function) and VAS for knee pain. Secondary outcome
measures were radiological features (joint space width, osteophyte
scores, subchondral sclerosis scores and tibio femoral alignment) and
KL grades. The serum levels of vitamin D were assessed by using
Enzyme Linked Immunosorbent Assay (ELISA) and calcium/phos-
phorus/alkaline phosphatase by UV end point method. Statistical
analysis was performed on an intension to treat basis.
Results: There was no signiﬁcant baseline difference of age, sex, anal-
gesic frequency, dietary vitamin D intake, serum levels of vitamin D,
calcium, phosphorus and alkaline phosphatase and in clinical and
radiological scores between the cases and controls. BMI (25.96 vs 25.65,
p¼0.75) and pain (10.94 vs 10.64, p¼0.66) was higher in the placebo
group although difference was not statistically signiﬁcant. There was no
signiﬁcant difference in radiological features and KL grades from
baseline and at 6 months in both the groups.
At six month, both the groups had an improvement inWOMAC and VAS
pain scores but vitamin D showed beneﬁt over placebo from baseline
(p<0.01); for WOMAC physical function vitamin D group showed
signiﬁcant improvement over placebo which remained same as their
baseline levels.
Conclusion: Although a long term study is being recommended to
establish radiological progression, if any, this short term randomized
placebo control trial yields a beneﬁcial effect of vitamin D in pain and
physical function outcomes in KOA. Vitamin D intake was beneﬁcial in
symptomatic improvement of KOA.42
OSTEOARTHRITIS DEVELOPMENT IN A SURGICALLY INDUCED RAT
MODEL IS ATTENUATED BY TREATMENT WITH MICRONIZED
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N.J. Willett, T. Thote, A.S. Lin, S. Moran, Y. Raji, H.Y. Stevens, R.E.
Guldberg. Georgia Inst. of Technology, Atlanta, GA, USA
Purpose: Osteoarthritis (OA) is currently the single most expensive
condition among medicare patients in the US; however, even with this
large economic burden, there is no intervention to modify disease
progression. Amniotic membrane is an allograft material that has anti-
inﬂammatory and anti-ﬁbrotic properties along with low immunoge-
nicity. It has been used in multiple clinical applications in humans
ranging from corneal defects to tendon repair; however it is the efﬁ-
cacy of amniotic membrane as an OA therapy is unknown. Objective:
To quantitatively assess the efﬁcacy of injectable micronized human
AM as a disease modifying intervention in a surgically induced rat
model of OA. Hypothesis: Micronized AM delivered intra-articularly
into the rat stiﬂe joint would attenuate OA disease progression and
that EPIC-mCT could be used to quantitatively evaluate the efﬁcacy of
this intervention.
Methods: OA was induced surgically by medial meniscal transection
(MMT) performed in Lewis rats (300g-325g). 24 hours after surgery, 50
ml micronized human AM (80mg/ml; AmnioFix Injectable, MiMedx
Group, Inc.) or saline was injected intra-articularly into the stiﬂe joint
(n¼5 per group, per time point). Animals were euthanized at 72 hours
or 21 days. Samples from the 21 day time point were dissected and
prepared for EPIC-mCT imaging using a contrast agent of 30% Hexabrix
320 (Covidien, Hazelwood, MO). For the quantitative EPIC-mCT analysis,
localized analysis was performed on the region of OA development, the
medial 1/3 of the medial tibial plateau, as well as at sites of focal lesions
(Fig 2). Quantitative measures of cartilage attenuation (inversely
proportional to proteoglycan content), lesion volume, and incidence of
lesion (greater than 50% loss in cartilage thickness) and erosion (loss of
thickness less than 50%) were obtained. Samples were then decalciﬁed
and stained with Saf-O or H&E. Data are presented as mean  standard
error and evaluated using an ANOVAwith Tukey's test. Signiﬁcance was
set at p < 0.05.
Results: Amnion injected into healthy, non-MMT, stiﬂe joints produced
no change in cartilage attenuation (i.e. proteoglycan content) and nolesions. In both MMT animals and healthy control animals, amnion
particles were identiﬁed histologically in the synovium at 3 and 21 days
post-surgery (Fig 1). The particles appeared as variably sized linear
fragments of multi-layered eosinophilic ﬁbrillar material. In saline
treated MMT animals 21 days post-surgery lesions and incidence of
erosion were observed along with an increase in cartilage attenuation
(indicating decreased proteoglycan content). Treatment with injectable
amnion inhibited lesion formation and reduced incidence of erosion as
compared to saline treated animals (table 1). Similarly, amnion treat-
ment reduced cartilage attenuation, indicating increased proteoglycan
content, by 78% compared to saline treatment.
Conclusion: This study demonstrated the efﬁcacy of a novel injectable
formulation of AM to attenuate osteoarthritis development in a rat
MMT model. AM injection produced signiﬁcantly higher proteoglycan
levels, fewer sites of erosion, and complete prevention of lesion
formation. Amnion is an allograft product that is currently used for
many clinical indications suggesting that the injectable formulation
could quickly be translated into a clinical OA therapy.
Figure 1. Histology from MMT animals with saline or amnion treatment. H&E images
(10) showed the presence of amnion particles (black arrows) in the synovium 3 days
post-injection. Saf-O staining 21 days post-injection showed healthy cartilage and
more proteoglycans staining in MMT animals treated with amnion.
Figure 2. EPIC-mCT data 21 days after MMT surgery. Reconstructions of the tibial
articular cartilage with attenuation heat maps show lesions in the saline treated
animals and sites of erosion in the amnion treated animals. No lesions were observed
in the amnion treated animals. Saline treated MMT animals showed a loss of proteo-
glycans (higher attenuation) while amnion treated animals showed proteoglycan
levels comparable to the non-MMT control.
